Silexion Therapeutics Ltd.
NASDAQ Global MarketTotal Valuation
Silexion Therapeutics Ltd. carries a market capitalization of 27,880.00, placing it among publicly traded companies globally. Its enterprise value stands at -424,000.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 27,880.00 |
| Enterprise Value | -424,000.00 |
Share Statistics
Silexion Therapeutics Ltd. currently has 339,486.00 shares outstanding.
| Shares Outstanding | 339,486.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Silexion Therapeutics Ltd. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 683.51, indicating elevated leverage, while an interest coverage ratio of -1,271.90 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.00 |
| Quick Ratio | 0.59 |
| Debt / Equity | 683.51 |
| Debt / EBITDA | -0.16 |
| Interest Coverage | -1,271.90 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -200.00 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 3,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Silexion Therapeutics Ltd.'s stock has gained approximately 25.50505% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.03.
| Beta (5Y) | N/A |
| 52-Week Price Change | 25.50505% |
| 50-Day Moving Average | 0.03 |
| 200-Day Moving Average | 0.03 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -12.72M, while operating income came in at -12.73M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -12.73M |
| Pretax Income | -12.91M |
| Net Income | -12.91M |
| EBITDA | -12.72M |
| EBIT | -12.73M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Silexion Therapeutics Ltd. holds 2.41M in cash and equivalents against 1.99M in total debt, resulting in a net debt position of -860,000.00. Total book value stands at -57.85M, with working capital of 5,000.00 providing operational flexibility.
| Cash & Cash Equivalents | 2.41M |
| Total Debt | 1.99M |
| Net Debt | -860,000.00 |
| Equity (Book Value) | -57.85M |
| Book Value Per Share | N/A |
| Working Capital | 5,000.00 |
Cash Flow
Silexion Therapeutics Ltd. produced -12.01M in operating cash flow over the past twelve months.
| Operating Cash Flow | -12.01M |
| Capital Expenditures | -3,000.00 |
| Free Cash Flow | -12.01M |
| FCF Per Share | N/A |
Scores
Silexion Therapeutics Ltd. posts an Altman Z-Score of -26.74, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -26.74 |